News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • North American farmers are postponing purchases of large tractors and combines as higher machinery, fertilizer, and fuel costs tighten budgets.
  • Crude oil and gasoline prices surged to multi-year highs.
  • Investors are focused on next week's March CPI, Fed minutes, and earnings season open to gauge inflation's impact.
  • U.S. reorganization of donated HIV and malaria supply chains risks interruptions to life-saving treatments in lower-income countries.
  • A French-owned CMA CGM container ship transited the Strait of Hormuz, marking a tentative resumption of Western-linked shipping.

Latest Articles

Joby, Uber Begin Dubai Air Taxi Bookings as Joby Shares Gain

Joby, Uber Begin Dubai Air Taxi Bookings as Joby Shares Gain

Joby Aviation and Uber launched an integrated air taxi booking option in Dubai called Uber Air powered by Joby. The service enables riders to request Joby’s all-electric vertical takeoff and landing aircraft through the Uber app, with Joby anticipating its first passengers in Dubai later this year. The announcement coincided with a 7.5% rise in Job…

U.S. Trade Representative Says Current China Tariff Levels Will Hold

U.S. Trade Representative Says Current China Tariff Levels Will Hold

U.S. Trade Representative Jamieson Greer told a television audience that the administration does not plan to widen its tariff program on China and expects the present tariff regime to remain. He confirmed talks with China have touched on excess capacity and said certain duties will be set at 15%, with the possibility that some could exceed that rat…

AMN Healthcare: Contrarian Buy — Margin Recovery and Deep Value Ahead

AMN Healthcare: Contrarian Buy — Margin Recovery and Deep Value Ahead

AMN Healthcare is trading below $21 with an enterprise value around $1.52B, P/S 0.29 and free cash flow of $233.8M. Operational leverage from Nurse & Allied and the rollout of WorkWise create a plausible path to margin recovery. Combine that with a depressed valuation and active short interest, and the stock is a contrarian setup for a mid-term reb…

Morgan Stanley Highlights European Ad Agencies With AI Strengths

Morgan Stanley Highlights European Ad Agencies With AI Strengths

Morgan Stanley says select European advertising groups are holding up well despite worries about AI-driven disruption, keeping a preferred stance on several stocks. The broker singles out Publicis Groupe as its leading overweight pick for its integrated model and data assets, while assigning equal-weight ratings to WPP, Havas and S4 Capital amid va…

Needham nudges Cytokinetics target to $85 as trial readout looms

Needham nudges Cytokinetics target to $85 as trial readout looms

Needham increased its price objective on Cytokinetics (CYTK) to $85 from $84 and kept a Buy rating, citing limited launch information for Myqorzo and focus on a second-quarter 2026 ACACIA-HCM trial readout in non-obstructive hypertrophic cardiomyopathy as the next major catalyst. The stock is trading near its 52-week high after a recent rally, whil…

Rosenblatt Cuts Workday Price Target to $150 After Disappointing Guidance

Rosenblatt Cuts Workday Price Target to $150 After Disappointing Guidance

Rosenblatt reduced its price target on Workday to $150 while preserving a Buy rating following the company’s fourth-quarter results and fiscal-year guidance. Workday reported quarter results that met consensus but flagged weakened bookings and issued revenue and profit guidance below expectations. Shares are trading near 52-week lows as multiple an…

Cantor Fitzgerald Keeps Overweight on Supernus, Flags ONAPGO Supply Gains

Cantor Fitzgerald Keeps Overweight on Supernus, Flags ONAPGO Supply Gains

Cantor Fitzgerald reiterated an Overweight rating and a $63.00 price target on Supernus Pharmaceuticals after the company reported stronger-than-expected fiscal 2025 results and provided an update on supply for ONAPGO. Revenue beat, high gross margins and guidance for ONAPGO underpinned the call; Stifel adjusted its target to $55 while keeping a Ho…

Cantor Fitzgerald Lowers Lucid Price Target After Weaker Production Plan

Cantor Fitzgerald Lowers Lucid Price Target After Weaker Production Plan

Cantor Fitzgerald cut its price target on Lucid Group Inc. to $14 from $21 while keeping a Neutral rating, citing a lower production outlook and continued margin deficits. Lucid posted stronger-than-expected revenue and record deliveries in the quarter, but a widening adjusted loss and a production forecast that falls short of consensus prompted th…